Kamada (KMDA) Competitors $6.91 -0.19 (-2.68%) Closing price 02/27/2025 04:00 PM EasternExtended Trading$6.83 -0.08 (-1.16%) As of 02/27/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends KMDA vs. TVTX, BLTE, VERA, IOVA, PRAX, GLPG, WVE, APGE, EVO, and IRONShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Travere Therapeutics Belite Bio Vera Therapeutics Iovance Biotherapeutics Praxis Precision Medicines Galapagos Wave Life Sciences Apogee Therapeutics Evotec Disc Medicine Kamada (NASDAQ:KMDA) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do insiders and institutionals hold more shares of KMDA or TVTX? 20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 4.1% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor KMDA or TVTX? Kamada received 237 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 65.98% of users gave Kamada an outperform vote while only 59.44% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32265.98% Underperform Votes16634.02% Travere TherapeuticsOutperform Votes8559.44% Underperform Votes5840.56% Which has more volatility & risk, KMDA or TVTX? Kamada has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Which has higher earnings and valuation, KMDA or TVTX? Kamada has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$158.38M2.51$8.28M$0.2824.68Travere Therapeutics$233.18M6.91-$111.40M-$4.10-5.03 Does the media prefer KMDA or TVTX? In the previous week, Travere Therapeutics had 24 more articles in the media than Kamada. MarketBeat recorded 30 mentions for Travere Therapeutics and 6 mentions for Kamada. Kamada's average media sentiment score of 0.26 beat Travere Therapeutics' score of 0.19 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Is KMDA or TVTX more profitable? Kamada has a net margin of 9.92% compared to Travere Therapeutics' net margin of -137.90%. Kamada's return on equity of 6.30% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Travere Therapeutics -137.90%-1,636.87%-55.95% Do analysts rate KMDA or TVTX? Kamada currently has a consensus target price of $14.50, suggesting a potential upside of 109.84%. Travere Therapeutics has a consensus target price of $30.62, suggesting a potential upside of 48.33%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 SummaryKamada beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$397.19M$7.12B$5.76B$8.48BDividend YieldN/A2.79%4.74%3.94%P/E Ratio24.686.1525.2119.07Price / Sales2.51184.14382.45108.76Price / Cash17.9065.6738.0634.58Price / Book1.636.467.464.39Net Income$8.28M$139.69M$3.19B$246.62M7 Day Performance-7.37%-4.50%-3.45%-3.46%1 Month Performance0.73%-6.28%-3.96%-5.01%1 Year Performance10.38%-13.64%11.62%6.46% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.0536 of 5 stars$6.91-2.7%$14.50+109.8%+8.0%$397.19M$158.38M24.68360Short Interest ↑TVTXTravere Therapeutics2.5424 of 5 stars$22.91-3.4%$27.77+21.2%+148.4%$1.79B$145.24M-5.04460Analyst ForecastAnalyst RevisionBLTEBelite Bio2.5696 of 5 stars$56.00-1.0%$96.33+72.0%+26.2%$1.78BN/A-50.4510News CoveragePositive NewsGap UpVERAVera Therapeutics2.3389 of 5 stars$27.46-19.7%$65.44+138.3%-38.9%$1.74BN/A-10.5240Earnings ReportAnalyst ForecastNews CoverageGap UpHigh Trading VolumeIOVAIovance Biotherapeutics4.2036 of 5 stars$5.57+4.3%$22.69+307.3%-69.9%$1.70B$1.19M-3.74500Earnings ReportNews CoveragePRAXPraxis Precision Medicines1.8203 of 5 stars$90.77+4.7%$145.20+60.0%+33.1%$1.69B$2.45M-8.81110GLPGGalapagos0.244 of 5 stars$25.44-0.2%$26.75+5.1%-28.3%$1.68B$259.40M0.001,123WVEWave Life Sciences4.0753 of 5 stars$10.81+0.1%$22.22+105.6%+107.1%$1.65B$113.31M-9.74240Analyst ForecastAPGEApogee Therapeutics2.9925 of 5 stars$36.54+0.8%$89.71+145.5%-12.3%$1.65BN/A-15.1091EVOEvotec1.8191 of 5 stars$4.58-0.2%$5.93+29.5%-42.6%$1.62B$845.74M0.005,061IRONDisc Medicine2.8032 of 5 stars$54.10flat$88.90+64.3%-17.7%$1.61BN/A-13.5930Earnings ReportAnalyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies Travere Therapeutics Alternatives Belite Bio Alternatives Vera Therapeutics Alternatives Iovance Biotherapeutics Alternatives Praxis Precision Medicines Alternatives Galapagos Alternatives Wave Life Sciences Alternatives Apogee Therapeutics Alternatives Evotec Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KMDA) was last updated on 2/28/2025 by MarketBeat.com Staff From Our Partners🚨My flagship system for just $0.99Right now, you can get a full year of my flagship trading program, Stealth Trades, for just 99 cents…Traders Agency | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredFrom $10K to $700K: The pattern is repeating (New Nvidia?)If you've ever thought "I missed Nvidia, and I'll never get another chance like that," this presentation is fo...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KMDA Stock Alerts